{"id":225,"date":"2023-09-13T10:00:00","date_gmt":"2023-09-13T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=225"},"modified":"2025-09-07T04:49:15","modified_gmt":"2025-09-07T04:49:15","slug":"china-bd-2023-insilico-medicine-and-exelixis-enters-a-license-on-usp1-inhibitor-ism3091","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/225.html","title":{"rendered":"[China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091"},"content":{"rendered":"\n<p>Announced Date: 2023-09-12 (September 12, 2023)<\/p>\n\n\n\n<p>Asset Name: ISM3091<\/p>\n\n\n\n<p>Licensor: InSilico Medicine (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Exelixis, Inc\uff08US\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small &nbsp;Molecule<\/p>\n\n\n\n<p>Asset Target: USP1 Inhibitor<\/p>\n\n\n\n<p>Potential Indication:  BRCA-mutant tumors<\/p>\n\n\n\n<p>Current Stage: IND clearance <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>&nbsp;Insilico granted&nbsp;Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds.&nbsp;<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp; $80 million,<\/p>\n\n\n\n<p>Development, commercial, and sales-based milestone payments, may up to $800 million .<\/p>\n\n\n\n<p>Tiered royalties on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/ir.exelixis.com\/news-releases\/news-release-details\/exelixis-and-insilico-medicine-enter-exclusive-global-license\">Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor | Exelixis, Inc.<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Insilico Medicine&nbsp; \u82f1\u77fd\u667a\u80fd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-09-12 (September 12, 2023) Asset Name: ISM3091 Licensor: InSilico Medicine (China) Licensee (Buyer): Exelixis, &hellip; <a title=\"[China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/225.html\"><span class=\"screen-reader-text\">[China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-225","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=225"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/225\/revisions"}],"predecessor-version":[{"id":229,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/225\/revisions\/229"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}